1-20 of 45
Ira Pastan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma

Christine Alewine, Mehwish Ahmad, Cody J. Peer, Zishuo I. Hu, Min-Jung Lee, Akira Yuno, Jessica D. Kindrick, Anish Thomas, Seth M. Steinberg, Jane B. Trepel, William D. Figg, Raffit Hassan, Ira Pastan
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (4): 828–836.
https://doi.org/10.1158/1078-0432.CCR-19-2586
Published: 14 February 2020
View article titled, Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma
Open the PDF for Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient–Derived Xenografts and Mesothelin as a Biomarker of Tumor Response

Jingli Zhang, Swati Khanna, Qun Jiang, Christine Alewine, Markku Miettinen, Ira Pastan, Raffit Hassan
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (6): 1564–1574.
https://doi.org/10.1158/1078-0432.CCR-16-1667
Published: 14 March 2017
View article titled, Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient–Derived Xenografts and Mesothelin as a Biomarker of Tumor Response
Open the PDF for Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient–Derived Xenografts and Mesothelin as a Biomarker of Tumor Response in another window
Includes: Supplementary data
Journal Articles

Wide Variability in the Time Required for Immunotoxins to Kill B Lineage Acute Lymphoblastic Leukemia Cells: Implications for Trial Design

Fabian Müller, Tyler Cunningham, Xiu Fen Liu, Alan S. Wayne, Ira Pastan
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (19): 4913–4922.
https://doi.org/10.1158/1078-0432.CCR-15-2500
Published: 02 October 2016
View article titled, Wide Variability in the Time Required for Immunotoxins to Kill B Lineage Acute Lymphoblastic Leukemia Cells: Implications for Trial Design
Open the PDF for Wide Variability in the Time Required for Immunotoxins to Kill B Lineage Acute Lymphoblastic Leukemia Cells: Implications for Trial Design in another window
Includes: Supplementary data
Journal Articles

New Life for Immunotoxin Cancer Therapy

Raffit Hassan, Christine Alewine, Ira Pastan
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (5): 1055–1058.
https://doi.org/10.1158/1078-0432.CCR-15-1623
Published: 29 February 2016
View article titled, New Life for Immunotoxin Cancer Therapy
Open the PDF for New Life for Immunotoxin Cancer Therapy in another window
Journal Articles

Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity

Robert J. Kreitman, Maryalice Stetler-Stevenson, Elaine S. Jaffe, Kevin C. Conlon, Seth M. Steinberg, Wyndham Wilson, Thomas A. Waldmann, Ira Pastan
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (2): 310–318.
https://doi.org/10.1158/1078-0432.CCR-15-1412
Published: 14 January 2016
View article titled, Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity
Open the PDF for Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity in another window
Journal Articles

Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma

Raffit Hassan, Hedy L. Kindler, Thierry Jahan, Lyudmila Bazhenova, Martin Reck, Anish Thomas, Ira Pastan, Jeff Parno, Daniel J. O'Shannessy, Penny Fatato, Julia D. Maltzman, Bruce A. Wallin
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (23): 5927–5936.
https://doi.org/10.1158/1078-0432.CCR-14-0804
Published: 30 November 2014
View article titled, Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma
Open the PDF for Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma in another window
Includes: Supplementary data
Journal Articles

Mesothelin-fc fusion protein detection using a novel microelectronic acoustic sensor platform

Anthony Dickherber, Christopher Corso, William Hunt, Ira Pastan, Mitchell Ho, Raffit Hassan
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19_Supplement): A26.
Published: 15 August 2014
View article titled, Mesothelin-fc fusion protein detection using a novel microelectronic acoustic sensor platform
Journal Articles

Minimal residual disease in hairy cell leukemia patients treated by BL22

Eugeny Arons, Joel Sunshine, Tara Suntum, Inger Margulies, Lynn Sorbara, Mark Raffeld, Maryalice Stetler-Stevenson, Ira Pastan, Robert J. Kreitman
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (19_Supplement): A51.
Published: 15 August 2014
View article titled, Minimal residual disease in hairy cell leukemia patients treated by BL22
Journal Articles

Recombinant antibody-based molecular therapeutics for brain tumor immunotherapy

Chien-Tsun Kuan, Kenji Wakiya, Jianjun Li, Stephen Keir, James Herndon, Carol Wikstrand, Michael Zalutsky, Ira Pastan, Darell Bigner
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (22_Supplement): A28.
Published: 15 August 2014
View article titled, Recombinant antibody-based molecular therapeutics for brain tumor immunotherapy
Journal Articles

Synergistic Antitumor Activity of Anti-CD25 Recombinant Immunotoxin LMB-2 with Chemotherapy

Rajat Singh, Yujian Zhang, Ira Pastan, Robert J. Kreitman
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (1): 152–160.
https://doi.org/10.1158/1078-0432.CCR-11-1839
Published: 02 January 2012
View article titled, Synergistic Antitumor Activity of Anti-CD25 Recombinant Immunotoxin LMB-2 with Chemotherapy
Open the PDF for Synergistic Antitumor Activity of Anti-CD25 Recombinant Immunotoxin LMB-2 with Chemotherapy in another window
Journal Articles

Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox

Robert J. Kreitman, Ira Pastan
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (20): 6398–6405.
https://doi.org/10.1158/1078-0432.CCR-11-0487
Published: 14 October 2011
View article titled, Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox
Open the PDF for Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox in another window
Journal Articles

Killing of Resistant Cancer Cells with Low Bak by a Combination of an Antimesothelin Immunotoxin and a TRAIL Receptor 2 Agonist Antibody

Xing Du, Laiman Xiang, Crystal Mackall, Ira Pastan
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (18): 5926–5934.
https://doi.org/10.1158/1078-0432.CCR-11-1235
Published: 14 September 2011
View article titled, Killing of Resistant Cancer Cells with Low Bak by a Combination of an Antimesothelin Immunotoxin and a TRAIL Receptor 2 Agonist Antibody
Open the PDF for Killing of Resistant Cancer Cells with Low Bak by a Combination of an Antimesothelin Immunotoxin and a TRAIL Receptor 2 Agonist Antibody in another window
Includes: Supplementary data
Journal Articles

Pentostatin Plus Cyclophosphamide Safely and Effectively Prevents Immunotoxin Immunogenicity in Murine Hosts

Miriam E. Mossoba, Masanori Onda, Justin Taylor, Paul R. Massey, Shirin Treadwell, Elad Sharon, Raffit Hassan, Ira Pastan, Daniel H. Fowler
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (11): 3697–3705.
https://doi.org/10.1158/1078-0432.CCR-11-0493
Published: 01 June 2011
View article titled, Pentostatin Plus Cyclophosphamide Safely and Effectively Prevents Immunotoxin Immunogenicity in Murine Hosts
Open the PDF for Pentostatin Plus Cyclophosphamide Safely and Effectively Prevents Immunotoxin Immunogenicity in Murine Hosts in another window
Journal Articles

Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers

Raffit Hassan, Steven J. Cohen, Martin Phillips, Ira Pastan, Elad Sharon, Ronan J. Kelly, Charles Schweizer, Susan Weil, Daniel Laheru
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (24): 6132–6138.
https://doi.org/10.1158/1078-0432.CCR-10-2275
Published: 16 December 2010
View article titled, Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers
Open the PDF for Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers in another window
Journal Articles

Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial

Alan S. Wayne, Robert J. Kreitman, Harry W. Findley, Glen Lew, Cynthia Delbrook, Seth M. Steinberg, Maryalice Stetler-Stevenson, David J. FitzGerald, Ira Pastan
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (6): 1894–1903.
https://doi.org/10.1158/1078-0432.CCR-09-2980
Published: 14 March 2010
View article titled, Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial
Open the PDF for Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial in another window
Journal Articles

Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P

Robert J. Kreitman, Raffit Hassan, David J. FitzGerald, Ira Pastan
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (16): 5274–5279.
https://doi.org/10.1158/1078-0432.CCR-09-0062
Published: 12 August 2009
View article titled, Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
Open the PDF for Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P in another window
Journal Articles

CAT-8015: A Second-Generation Pseudomonas Exotoxin A–Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies

Ralph F. Alderson, Robert J. Kreitman, Tianling Chen, Peter Yeung, Ronald Herbst, Judy A. Fox, Ira Pastan
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (3): 832–839.
https://doi.org/10.1158/1078-0432.CCR-08-1456
Published: 02 February 2009
View article titled, CAT-8015: A Second-Generation <em>Pseudomonas</em> Exotoxin A–Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies
Open the PDF for CAT-8015: A Second-Generation <em>Pseudomonas</em> Exotoxin A–Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies in another window
Journal Articles

High Shed Antigen Levels within Tumors: An Additional Barrier to Immunoconjugate Therapy

Yujian Zhang, Ira Pastan
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (24): 7981–7986.
https://doi.org/10.1158/1078-0432.CCR-08-0324
Published: 15 December 2008
View article titled, High Shed Antigen Levels within Tumors: An Additional Barrier to Immunoconjugate Therapy
Open the PDF for High Shed Antigen Levels within Tumors: An Additional Barrier to Immunoconjugate Therapy in another window
Journal Articles

Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers

Raffit Hassan, Susie Bullock, Ahalya Premkumar, Robert J. Kreitman, Hedy Kindler, Mark C. Willingham, Ira Pastan
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (17): 5144–5149.
https://doi.org/10.1158/1078-0432.CCR-07-0869
Published: 04 September 2007
View article titled, Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers
Open the PDF for Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers in another window
Journal Articles

A Phase I Clinical Trial of Single-Dose Intrapleural IFN-β Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses

Daniel H. Sterman, Adri Recio, Richard G. Carroll, Colin T. Gillespie, Andrew Haas, Anil Vachani, Veena Kapoor, Jing Sun, Richard Hodinka, Jennifer L. Brown, Michael J. Corbley, Michael Parr, Mitchell Ho, Ira Pastan, Michael Machuzak, William Benedict, Xin-qiao Zhang, Elaina M. Lord, Leslie A. Litzky, Daniel F. Heitjan, Carl H. June, Larry R. Kaiser, Robert H. Vonderheide, Steven M. Albelda
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (15): 4456–4466.
https://doi.org/10.1158/1078-0432.CCR-07-0403
Published: 01 August 2007
View article titled, A Phase I Clinical Trial of Single-Dose Intrapleural IFN-β Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses
Open the PDF for A Phase I Clinical Trial of Single-Dose Intrapleural IFN-β Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses in another window